Medication and biomarkers*
| Number of patients | 2225 |
| Blood eosinophil count (N/109 L) | 0.33 (0.16, 0.60) |
| Highest blood eosinophil count (N/109 L)† | 0.62 (0.40, 1.00) |
| FeNO (ppb) | 39.0 (20.0, 75.0) |
| IgE (IU/mL) | 181 (60, 480) |
| Maintenance oral steroids | 1142 (51.7%) |
| Maintenance oral steroid dose (mg) | 10 (5, 15) |
| Inhaled steroid dose (mcg, BDP equivalent) | 2000 (1600, 2000) |
| LAMA | 1161 (53.5%) |
| Theophylline | 595 (27.2%) |
| SABA | 2089 (95.1%) |
| Leukotriene receptor antagonist | 1048 (48.9%) |
| Maintenance macrolide | 199 (9.3%) |
| Nebuliser | 533 (24.5%) |
| Prior anti-IgE therapy | 251 (11.5%) |
| Initiate/continue biologic therapy | 1524 (68.9%) |
| Biologic therapy name | |
| Omalizumab | 329 (22.6%) |
| Dupilumab | 5 (0.3%) |
| Mepolizumab | 731 (50.3%) |
| Benralizumab | 380 (26.1%) |
| Reslizumab | 9 (0.6%) |
*Mean (SD), median (IQR) or count (%) as appropriate.
†Highest blood count is the highest recorded in available prior medical records.
FeNO, fractional exhaled nitric oxide; LAMA, long-acting antimuscarinic antagonist; SABA, short acting β2-agonist.